Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 35,566 Shares of Abbott Laboratories $ABT

Key Points

• Loring Wolcott & Coolidge Fiduciary Advisors reduced its Abbott Laboratories stake by 35,566 shares, or 2.3%, leaving it with 1.53 million shares valued at approximately $151.3 million. Institutional investors and hedge funds collectively own 75.18% of Abbott.
• Abbott’s third-quarter results broadly met expectations, with adjusted EPS of $1.42 and revenue of $13.01 billion, up 14.5% year over year. However, investors remain concerned about the company’s lowered 2026 growth outlook, diabetes-related pricing pressure and weakness in electrophysiology.
• Wall Street’s outlook remains broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $118.32 versus the stock’s $103.70 opening price. Abbott also announced a quarterly dividend of $0.63 per share, equivalent to a 2.4% annualized yield.

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 2.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,530,620 shares of the healthcare product maker's stock after selling 35,566 shares during the period. Abbott Laboratories comprises about 1.4% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's investment portfolio, making the stock its 22nd biggest holding. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned about 0.09% of Abbott Laboratories worth $151,271,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. BlackRock Inc. increased its holdings in Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after buying an additional 6,769,518 shares during the last quarter. State Street Corp lifted its holdings in Abbott Laboratories by 1.7% during the 2nd quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker's stock worth $7,343,246,000 after buying an additional 1,350,766 shares during the last quarter. Bank of America Corp DE bought a new position in Abbott Laboratories during the 2nd quarter worth approximately $1,603,607,000. Deutsche Bank AG lifted its holdings in Abbott Laboratories by 18.6% during the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker's stock worth $1,515,963,000 after buying an additional 2,614,965 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Abbott Laboratories in the 2nd quarter worth approximately $1,082,524,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
• Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
• Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
• Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
• Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
• Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ABT. JPMorgan Chase & Co. lowered their price target on Abbott Laboratories from $120.00 to $118.00 and set an "overweight" rating for the company in a report on Thursday. Rothschild & Co Redburn raised Abbott Laboratories from a "neutral" rating to a "buy" rating and upped their price target for the company from $119.00 to $127.00 in a research report on Friday, October 2nd. Weiss Ratings upgraded Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 18th. Robert W. Baird lifted their price objective on shares of Abbott Laboratories from $121.00 to $123.00 and gave the stock an "outperform" rating in a report on Thursday. Finally, Citigroup lowered their target price on shares of Abbott Laboratories from $125.00 to $122.00 and set a "buy" rating for the company in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $118.32.

Abbott Laboratories Stock Up 0.0%

Shares of Abbott Laboratories stock opened at $103.70 on Monday. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The business's 50 day simple moving average is $105.15 and its 200-day simple moving average is $98.29. The stock has a market capitalization of $179.45 billion, a price-to-earnings ratio of 38.70, a PEG ratio of 1.82 and a beta of 0.59. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $132.02.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The business had revenue of $13.01 billion for the quarter, compared to the consensus estimate of $12.99 billion. During the same quarter last year, the business posted $1.30 EPS. The business's revenue was up 14.5% on a year-over-year basis. Equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 94.03%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.